Repurposing Benztropine, Natamycin, and Nitazoxanide Using Drug Combination and Characterization of Gastric Cancer Cell Lines

Gastric cancer (GC) ranked as the fifth most incident cancer in 2020 and the third leading cause of cancer mortality. Surgical prevention and radio/chemotherapy are the main approaches used in GC treatment, and there is an urgent need to explore and discover innovative and effective drugs to better treat this disease. A new strategy arises with the use of repurposed drugs. Drug repurposing coupled with drug combination schemes has been gaining interest in the scientific community. The main objective of this project was to evaluate the therapeutic effects of alternative drugs in GC. For that, three GC cell lines (AGS, MKN28, and MKN45) were used and characterized. Cell viability assays were performed with the reference drug 5-fluororacil (5-FU) and three repurposed drugs: natamycin, nitazoxanide, and benztropine. Nitazoxanide displayed the best results, being active in all GC cells. Further, 5-FU and nitazoxanide in combination were tested in MKN28 GC cells, and the results obtained showed that nitazoxanide alone was the most promising drug for GC therapy. This work demonstrated that the repurposing of drugs as single agents has the ability to decrease GC cell viability in a concentration-dependent manner.

[1]  N. Vale,et al.  Drug Repurposing in Cancer Therapy: Influence of Patient’s Genetic Background in Breast Cancer Treatment , 2022, International journal of molecular sciences.

[2]  A. Jha,et al.  A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19 , 2022, COVID.

[3]  N. Vale,et al.  Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells , 2022, Biomolecules.

[4]  P. Xia,et al.  Reversine inhibits proliferation, invasion and migration and induces cell apoptosis in gastric cancer cells by downregulating TTK , 2021, Experimental and therapeutic medicine.

[5]  N. El-Najjar,et al.  Repurposing of Antimicrobial Agents for Cancer Therapy: What Do We Know? , 2021, Cancers.

[6]  C. Kundu,et al.  5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  A. Kesselheim,et al.  Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997 , 2021, Journal of pharmaceutical policy and practice.

[8]  B. Bedogni,et al.  Wound Healing Assay for Melanoma Cell Migration. , 2021, Methods in molecular biology.

[9]  M. Kook,et al.  Predictive value of E-cadherin and EpCAM for detection of metastatic lymph node in early gastric cancer , 2020, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[10]  A. Mostafa,et al.  Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? , 2020, Journal of Genetic Engineering and Biotechnology.

[11]  E. Nice,et al.  Overcoming cancer therapeutic bottleneck by drug repurposing , 2020, Signal Transduction and Targeted Therapy.

[12]  G. Monteleone,et al.  Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System , 2020, International journal of molecular sciences.

[13]  K. Tao,et al.  A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer , 2020, OncoTargets and therapy.

[14]  M. Takigawa,et al.  Antiparkinson Drug Benztropine Suppresses Tumor Growth, Circulating Tumor Cells, and Metastasis by Acting on SLC6A3/DAT and Reducing STAT3 , 2020, Cancers.

[15]  Jamie N. Brown,et al.  Treatment of Helicobacter pylori with nitazoxanide-containing regimens: a systematic review , 2020, Infectious diseases.

[16]  W. González,et al.  TASK-3 Gene Knockdown Dampens Invasion and Migration and Promotes Apoptosis in KATO III and MKN-45 Human Gastric Adenocarcinoma Cell Lines , 2019, International journal of molecular sciences.

[17]  I. Agoulnik,et al.  Inhibition of base excision repair by natamycin suppresses prostate cancer cell proliferation. , 2019, Biochimie.

[18]  Maria Sofia Fernandes,et al.  Clinical spectrum and pleiotropic nature of CDH1 germline mutations , 2019, Journal of Medical Genetics.

[19]  Allen W. Zhang,et al.  Cancer stemness, intratumoral heterogeneity, and immune response across cancers , 2018, Proceedings of the National Academy of Sciences.

[20]  Yan Gao,et al.  Establishment and characterization of a GES-1 human gastric epithelial cell line stably expressing miR-23a , 2018, Oncology letters.

[21]  Mingfei Wang,et al.  Effects of glabridin combined with 5-fluorouracil on the proliferation and apoptosis of gastric cancer cells , 2018, Oncology letters.

[22]  N. André,et al.  Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? , 2018, European Respiratory Review.

[23]  M. Ritter,et al.  Miniaturization of the Clonogenic Assay Using Confluence Measurement , 2018, International journal of molecular sciences.

[24]  Z. Kavosi,et al.  Risk Factors for Gastric Cancer: A Systematic Review , 2018, Asian Pacific journal of cancer prevention : APJCP.

[25]  S. Papapetropoulos,et al.  Drug repurposing from the perspective of pharmaceutical companies , 2018, British journal of pharmacology.

[26]  K. Kalland,et al.  Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer. , 2018, Nature chemical biology.

[27]  Michael Pryszlak,et al.  Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics , 2017, Front. Oncol..

[28]  A. German,et al.  Gastric carcinoma in canines and humans, a review , 2017, Veterinary and comparative oncology.

[29]  Yuanyu Wu,et al.  Progress in the treatment of advanced gastric cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[30]  F. Safari,et al.  Evaluation of Cell- Morphological Changes by Helicobacter pylori CagA and Pragmin in AGS Human Gastric Carcinoma Cells , 2017 .

[31]  A. Kaur,et al.  Wound Healing Concepts in Clinical Practice of OMFS , 2017, Journal of Maxillofacial and Oral Surgery.

[32]  Jin-bo Gao,et al.  Molecular mechanisms of chemoresistance in gastric cancer , 2016, World journal of gastrointestinal oncology.

[33]  Qi Zhang,et al.  Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing , 2016, Oncology letters.

[34]  L. Qu,et al.  Nuclear transcription factor CDX2 inhibits gastric cancer‑cell growth and reverses epithelial‑to‑mesenchymal transition in vitro and in vivo. , 2015, Molecular medicine reports.

[35]  J. Sweasy,et al.  Gastric cancer associated variant of DNA polymerase beta (Leu22Pro) promotes DNA replication associated double strand breaks , 2015, Oncotarget.

[36]  Yun-En Liu,et al.  NaCl pretreatment attenuates H.pylori-induced DNA damage and exacerbates proliferation of gastric epithelial cells (GES-1) , 2015, Infectious Agents and Cancer.

[37]  Ling Huang,et al.  5-Fluorouracil Chemotherapy of Gastric Cancer Generates Residual Cells with Properties of Cancer Stem Cells , 2015, International journal of biological sciences.

[38]  J. Black,et al.  Nitazoxanide Use as Part of an Empiric Multi-Drug Regimen in Treating Children with Suspected Helicobacter pylori Infection , 2014, Case Reports in Gastroenterology.

[39]  Kuan-song Wang,et al.  Epidermal Growth Factor-Like Domain-Containing Protein 7 (EGFL7) Enhances EGF Receptor−AKT Signaling, Epithelial−Mesenchymal Transition, and Metastasis of Gastric Cancer Cells , 2014, PloS one.

[40]  S. Gambhir,et al.  A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide , 2013, Molecular Cancer Therapeutics.

[41]  M. Rezaei-Tavirani,et al.  Flow Cytometry Analysis of Rosa Damascena Effects on Gastric Cancer Cell Line (MKN45) , 2013 .

[42]  W. El-Rifai,et al.  Silencing of Glutathione Peroxidase 3 through DNA Hypermethylation Is Associated with Lymph Node Metastasis in Gastric Carcinomas , 2012, PloS one.

[43]  S. Cai,et al.  Tumor‐associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer , 2012, Journal of surgical oncology.

[44]  N. Shah,et al.  A Randomized Study Comparing Levofloxacin, Omeprazole, Nitazoxanide, and Doxycycline versus Triple Therapy for the Eradication of Helicobacter pylori , 2011, The American Journal of Gastroenterology.

[45]  J. Bussink,et al.  Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[46]  N. Sarma,et al.  Colony forming cell (CFC) assay for human hematopoietic cells. , 2010, Journal of visualized experiments : JoVE.

[47]  Sylvia E. Le Dévédec,et al.  Systems microscopy approaches to understand cancer cell migration and metastasis , 2010, Cellular and Molecular Life Sciences.

[48]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[49]  J. Wastling,et al.  Thiazolides inhibit growth and induce glutathione‐S‐transferase Pi (GSTP1)‐dependent cell death in human colon cancer cells , 2008, International journal of cancer.

[50]  Ning Zhang,et al.  5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies , 2008, Molecules.

[51]  H. Riezman,et al.  Natamycin Blocks Fungal Growth by Binding Specifically to Ergosterol without Permeabilizing the Membrane* , 2008, Journal of Biological Chemistry.

[52]  D. Weiss Chapter 11 – Neutrophil Function , 2008 .

[53]  Goberdhan P Dimri,et al.  Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. , 2007, Methods in molecular biology.

[54]  B. Madras,et al.  Dopamine Transporter (DAT) Inhibitors Alleviate Specific Parkinsonian Deficits in Monkeys: Association with DAT Occupancy in Vivo , 2006, Journal of Pharmacology and Experimental Therapeutics.

[55]  S. Runyon,et al.  Dopamine transporter ligands: recent developments and therapeutic potential. , 2006, Current topics in medicinal chemistry.

[56]  A. Neugut,et al.  Epidemiology of gastric cancer. , 2006, World journal of gastroenterology.

[57]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[58]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[59]  K. Walen The origin of transformed cells. studies of spontaneous and induced cell transformation in cell cultures from marsupials, a snail, and human amniocytes. , 2002, Cancer genetics and cytogenetics.

[60]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[61]  K. Kinzler,et al.  Genetic instability in colorectal cancers , 1997, Nature.

[62]  R. Moll,et al.  Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[63]  T. Motoyama,et al.  COMPARISON OF SEVEN CELL LINES DERIVED FROM HUMAN GASTRIC CARCINOMAS , 1986, Acta pathologica japonica.

[64]  C. Heidelberger,et al.  Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds , 1957, Nature.

[65]  J. Diagnostic Immunohistochemistry , 2022 .